How I treat newly diagnosed acute lymphoblastic leukemia.

Clin Hematol Int · 2024 · PMC11088446 · PMID 38817308

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

However, the differences in EFS and overall survival (OS) did not reach statistical significance. 22 Blinatumomab, a bispecific anti-CD19/anti-CD3 T-cell enhancer, has been approved for treating patients in CR with MRD levels>10 -3 in the bone marrow.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.